The Timing for Primary Prevention for ICD in the Current Era of Pharmacotherapy

Area of Science:

• Cardiology
• Pharmacological Therapy
• Medical Device Implantation

Background:

• Recent pharmacological advances have improved outcomes in heart failure with reduced ejection fraction (HFrEF).
• The optimal timing for implantable cardioverter-defibrillator (ICD) placement for primary prevention in HFrEF remains under discussion.
• Guideline-directed medical therapy (GDMT) is crucial for managing HFrEF patients.

Purpose of the Study:

• To provide an updated perspective on the timing of ICD implantation in HFrEF patients receiving optimal GDMT.
• To evaluate the impact of reverse cardiac remodeling (RCR) and residual sudden cardiac death (SCD) risk on ICD timing.
• To inform clinical decision-making regarding primary prevention ICDs in HFrEF.

Main Methods:

• Review of current evidence on HFrEF treatment and ICD implantation.
• Analysis of the temporal relationship between optimal GDMT, RCR, and SCD risk.
• Consideration of individual patient factors influencing RCR and SCD risk.

Main Results:

• Clinically significant RCR typically occurs more than 3 months after initiating optimal GDMT.
• Residual SCD risks can be low in specific HFrEF populations even with GDMT.
• Non-competing risks of death must be considered alongside SCD risk.

Conclusions:

• ICD implantation timing in HFrEF should consider the potential for RCR beyond 3 months of GDMT.
• Individualized assessment of RCR and SCD risk modulators is essential.
• Further development and validation of risk stratification algorithms are needed for optimal primary prevention ICD timing.